Lymphoblastic lymphoma
MONDO:0000873A lymphoma composed of immature small to medium-sized precursor lymphoid cells (lymphoblasts). It includes the B- and T-cell lymphoblastic lymphoma.
Also known as: lymphoblastic lymphoma, lymphoma, lymphoblastic, malignant, precursor cell lymphoblastic lymphoma, precursor lymphoblastic lymphoma, lymphoma, lymphoblastic
2024 clinical trials for this condition and its sub-types, 78 tagged with Lymphoblastic lymphoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Lymphoblastic lymphoma
-
T-lymphoblastic lymphoma 32 trials
-
New vaccine aims to shield transplant patients from deadly virus
Vaccine OngoingThis phase II trial tests a vaccine designed to protect stem cell transplant recipients from cytomegalovirus (CMV), a common virus that can cause serious illness in people with weakened immune systems. The vaccine uses a modified, harmless virus to deliver three CMV proteins, tra…
Phase 2 • Sponsor: City of Hope Medical Center • Aim: Vaccine
Last updated Jul 30, 2026 00:00 UTC
-
New vaccine aims to shield transplant patients from deadly virus
Vaccine OngoingThis study tests a vaccine called Triplex to prevent cytomegalovirus (CMV) infection in adults who have received a stem cell transplant. CMV is usually harmless but can be life-threatening for people with weakened immune systems. The vaccine uses harmless virus pieces to train th…
Phase 2 • Sponsor: City of Hope Medical Center • Aim: Vaccine
Last updated Jun 27, 2026 07:57 UTC
-
Adult leukemia patients get Kid-Style chemo combo in new trial
Disease control OngoingThis phase 2 trial is testing whether a combination of chemotherapy drugs typically used in children can be safe and effective for adults aged 18 to 60 with newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL). The study aims to see if this 'pediatr…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Could removing certain immune cells prevent a deadly transplant complication?
Disease control OngoingThis study tests whether removing a specific type of immune cell (naive T cells) from donor stem cells can prevent chronic graft-versus-host disease (GVHD) in children and young adults with blood cancers. GVHD occurs when donor cells attack the patient's body after a stem cell tr…
Phase 2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Triple-Target CAR t cells take on tough blood cancers
Disease control OngoingThis early-phase trial tests a new type of immunotherapy called TriCAR19.20.22 T cells for people with certain blood cancers (non-Hodgkin lymphoma, acute lymphoblastic leukemia, and chronic lymphocytic leukemia) that have returned or not responded to standard treatments. The ther…
Phase 1 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Promising combo targets tough leukemia in early trial
Disease control OngoingThis study tests a combination of two drugs—venetoclax and vincristine—in people with T-cell or B-cell acute lymphoblastic leukemia that has returned or not responded to prior treatment. The goal is to find the safest dose and see if the combo can lead to remission. About 40 adul…
Phase 1/2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Promising combo therapy aims to beat back childhood blood cancers
Disease control OngoingThis large phase 3 study tests whether adding the drug blinatumomab to standard chemotherapy can improve outcomes for children and young adults with newly diagnosed B-cell acute lymphoblastic leukemia or lymphoma, including those with Down syndrome. The trial enrolls over 6,700 p…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
New hope for kids with tough leukemia: targeted Antibody-Drug combo shows promise
Disease control OngoingThis study tests a drug called inotuzumab ozogamicin in children and young adults (ages 1 to 21) whose B-cell acute lymphoblastic leukemia (B-ALL) has returned or not responded to standard treatment. The drug works like a guided missile, attaching to a marker (CD22) on cancer cel…
Phase 2 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
Could adding bortezomib boost chemo for young blood cancer patients?
Disease control OngoingThis study tests whether adding the drug bortezomib to standard chemotherapy helps children and young adults (ages 1 to 30) with newly diagnosed T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma. About 847 participants received either standard chemo alone or ch…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
New chemo drug could mean fewer shots for kids with leukemia
Disease control OngoingThis study compares two forms of the chemotherapy drug asparaginase in 240 children and teens with acute lymphoblastic leukemia or lymphoblastic lymphoma. One drug (Oncaspar) is given every 2 weeks, while the new drug (SC-PEG) is given every 3 weeks and may last longer in the blo…
Phase 2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
New combo therapy aims to outsmart leukemia in older patients
Disease control OngoingThis phase II trial is testing whether adding a targeted drug called inotuzumab ozogamicin to standard chemotherapy can help older adults with B-cell acute lymphoblastic leukemia or lymphoma. The study compares the combination to standard chemo alone in 68 participants. The goal …
Phase 2 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Engineered T-Cells take on tough lymphoma in early trial
Disease control OngoingThis phase I trial tests a new approach for patients with high-risk or recurrent non-Hodgkin lymphoma. After a stem cell transplant, participants receive a single infusion of their own genetically modified T-cells designed to recognize and attack cancer cells. The study aims to f…
Phase 1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope for kids with blood cancer: tailored treatments aim to boost cure rates and cut side effects
Disease control OngoingThis study tests whether using each child's unique genetic information to guide treatment can improve outcomes for acute lymphoblastic leukemia and lymphoma. About 790 children aged 1-18 will receive a combination of chemotherapy and newer targeted therapies, such as CAR T cells …
Phase 2/3 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Can a children's chemo recipe help adults with leukemia? early trial adds venetoclax to the mix.
Disease control OngoingThis early-phase trial tests whether adding venetoclax to a chemotherapy regimen originally designed for children is safe and effective for adults under 60 with newly diagnosed acute lymphoblastic leukemia (ALL). The study involves 12 participants and focuses on finding the right…
Early phase 1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New stem cell method shows promise for young blood cancer patients
Disease control OngoingThis study tests a new way to do stem cell transplants for children and young adults (up to age 22) with blood cancers like leukemia. Doctors remove certain immune cells from donated stem cells to lower the risk of graft-versus-host disease, a serious complication. The goal is to…
Phase 2 • Sponsor: Julie-An M. Talano • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New chemo cocktail aims to boost survival in kids with rare lymphoma
Disease control OngoingThis phase 3 trial is testing a modified chemotherapy regimen for 150 Chinese children and adolescents newly diagnosed with lymphoblastic lymphoma. The goal is to improve event-free survival compared to previous results. Participants receive a combination of drugs including predn…
Phase 3 • Sponsor: Children's Cancer Group, China • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Experimental CAR t therapy targets tough leukemia in first human trial
Disease control OngoingThis early-phase study tests a new type of immunotherapy called BAFFR-CAR T cells for adults with B-cell acute lymphoblastic leukemia that has come back or not responded to at least two prior treatments. The therapy involves reprogramming a patient's own immune cells to recognize…
Phase 1 • Sponsor: PeproMene Bio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New strategy aims to tame common virus after stem cell transplants
Disease control OngoingThis study tests a modified plan to prevent and treat cytomegalovirus (CMV) infection in people with blood cancers who have had a donor stem cell transplant. CMV is a common virus that can cause serious problems after transplant. The study involves 153 participants and looks at w…
Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New drug combo shows promise in early trial for tough blood cancer
Disease control OngoingThis early-phase study tests whether combining two drugs, venetoclax and inotuzumab ozogamicin, is safe and effective for people with B-cell acute lymphoblastic leukemia (B-ALL), a fast-growing blood cancer. About 23 adults whose cancer has returned or not responded to treatment …
Phase 1 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New stem cell method aims to cut transplant risks for blood cancer patients
Disease control OngoingThis study tests a stem cell transplant method that removes certain immune cells (T and B cells) from donated stem cells before giving them to patients with blood cancers like leukemia or lymphoma. The goal is to help the new cells grow (engraft) while reducing the risk of graft-…
Phase 2 • Sponsor: Children's Hospital of Philadelphia • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Liver shield: nutrient may prevent chemo side effect in young leukemia patients
Symptom relief OngoingThis study tests whether adding levocarnitine, a natural nutrient, to standard chemotherapy can prevent severe liver damage in teens and young adults (ages 15-39) with leukemia or lymphoma. About 440 participants will receive either chemotherapy alone or chemotherapy plus levocar…
Phase 3 • Sponsor: Children's Oncology Group • Aim: Symptom relief
Last updated Aug 23, 2026 00:00 UTC
-
Parent training may boost school success for latino kids with cancer
Symptom relief OngoingThis study tests whether a high-intensity parenting program can improve learning and school functioning in Latino children being treated for leukemia or lymphoma. About 214 parents and children will take part. Parents in the high-intensity group will receive extra training in ski…
Sponsor: City of Hope Medical Center • Aim: Symptom relief
Last updated Jun 27, 2026 12:24 UTC
-
Digital tools aim to close learning gaps for young cancer survivors
Knowledge-focused OngoingThis study tests whether a special website and video coaching for parents can help children aged 6-12 who had leukemia or lymphoma improve their learning and school performance. Many children survive these cancers but may struggle with memory, attention, and thinking due to treat…
Sponsor: City of Hope Medical Center • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
Scientists launch tissue bank to unlock secrets of rare blood cancers
Knowledge-focused OngoingThis study collects bone marrow and blood samples, along with medical history, from people with multiple myeloma, Waldenstrom macroglobulinemia, and related disorders. The samples are stored in a tissue bank for future research to understand what causes these cancers, how they pr…
Sponsor: Dana-Farber Cancer Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC